Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil vs Remimazolam/Dexmedetomidine for Awake Fibreoptic Nasotracheal Intubation
NCT06581731Completed
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of remimazolam and dexmedetomidine in difficult intubation (DI) (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: Vocal cord mobility, Cough response and 1 more. Started Jun 2024; status: completed.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
difficult intubation (DI)
Beyond the preview
Go deeper on NCT06581731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581731.